Alcidion GroupASX:ALC -4.76% 3-Year ROIIC % is 68.91 as of Jun. 2025. The stock has 4 warning signs investors should review. Among 619 Healthcare Providers & Services companies, Alcidion Group ranks better than 86.59% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Alcidion Group's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 68.91%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Alcidion Group's 3-Year ROIIC % or its related term are showing as below:
ASX:ALC's 3-Year ROIIC % is ranked better than 86.59% of 619
companies
in the Healthcare Providers & Services industry
Industry Median: 3.28
vs ASX:ALC: 68.91
Alcidion Group (ASX:ALC) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Alcidion Group 3-Year ROIIC % Related Terms
Alcidion Group 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Alcidion Group's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ALC vs VEEV, BTSG, TEM: 3-Year ROIIC % Comparison
For the Health Information Services subindustry, Alcidion Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alcidion Group 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Alcidion Group's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Alcidion Group's 3-Year ROIIC % falls into.
Alcidion Group's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -9.122 (Jun. 2025) - -1.728 (Jun. 2022) )
/
( 110.526 (Jun. 2025) - 121.256 (Jun. 2022) )
=
-7.394
/
-10.73
=
68.91%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Alcidion Group (ASX:ALC) has a 3-Year ROIIC % of 68.91 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Alcidion Group and its competitors. According to the industry distribution chart, Alcidion Group ranks #83 out of 619 companies in the Healthcare Providers & Services industry, placing it in the top 13.4%.
Is Alcidion Group's 3-Year ROIIC % too high?
Alcidion Group's current 3-Year ROIIC % is 68.91. The Healthcare Providers & Services industry median 3-Year ROIIC % is 3.28. Alcidion Group's value of 68.91 is 2000.9% above this industry median. Based on the distribution chart, Alcidion Group ranks #83 out of 619 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Alcidion Group's 3-Year ROIIC % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Alcidion Group ranks #83 out of 619 companies for 3-Year ROIIC %. This places Alcidion Group in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.28. Alcidion Group's value of 68.91 is 2000.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.28, based on 619 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alcidion Group's current 3-Year ROIIC % of 68.91 is 2000.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Alcidion Group and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alcidion Group's current 3-Year ROIIC % is 68.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcidion Group stock overvalued right now?
Based on GuruFocus' analysis, Alcidion Group (ASX:ALC) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.12, compared to a current price of A$0.10 — trading 16.7% below its estimated fair value. The current 3-Year ROIIC % is 68.91 and 2000.9% above the Healthcare Providers & Services industry median of 3.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Alcidion Group (ASX:ALC), the current 3-Year ROIIC % is 68.91 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alcidion Group Ltd is a provider of intelligent informatics software. It offers a fully integrated digital patient care platform that includes a clinical decision support (CDS) system, Electronic Patient Record (EPR), and Patient Administration System (PAS). Alcidion is engaged in the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and PAS), the reselling of healthcare software products from its strategic partners, and the delivery of product implementation, product support and maintenance, systems integration and data analysis services to healthcare customers in the United Kingdom, Australia, and New Zealand. The company generates maximum revenue from the United Kingdom.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ALC has been successfully added to your 